The MCAS-POTS-EDS Triad: Understanding the Connection

Mast cell activation syndrome (MCAS), postural orthostatic tachycardia syndrome (POTS), and Ehlers-Danlos syndrome (EDS) cluster together because all three trace back to the same connective tissue, which anchors the mast cells and blood vessels that misfire when that tissue is structurally weak. Kohn and Chang (2020) report that more than half of people with hypermobile EDS (hEDS) also meet criteria for MCAS, and a comparable share show dysautonomia consistent with POTS, which is why clinicians and patients call the combination the triad.

If you have one of these conditions, there’s a good chance someone – a doctor, a fellow patient, an online support group – has asked whether you’ve been evaluated for the other two. And if you’re dealing with all three, you know the particular frustration of having a body that seems to malfunction in every system simultaneously, while most doctors only look at one piece of the puzzle.

The co-occurrence of mast cell activation syndrome (MCAS), postural orthostatic tachycardia syndrome (POTS), and Ehlers-Danlos syndrome (EDS) – particularly the hypermobile type (hEDS) – is one of the most significant patterns in complex chronic illness. It’s not a coincidence, and it’s not just “bad luck.” There are plausible biological mechanisms that explain why these three conditions travel together, and understanding those mechanisms has real implications for diagnosis and treatment.

The Three Conditions: A Brief Overview

Before diving into their connections, let’s make sure we’re on the same page about what each condition involves:

Ehlers-Danlos Syndrome (EDS) is a group of connective tissue disorders caused by defects in collagen and other structural proteins. The hypermobile type (hEDS) – the most common form – is characterized by joint hypermobility, chronic pain, frequent subluxations or dislocations, and fragile or stretchy skin. Connective tissue is the scaffolding of the body; it’s everywhere. When it’s defective, the effects are bodywide.

Mast Cell Activation Syndrome (MCAS) is a condition in which mast cells – immune cells found in connective tissue throughout the body – become hyperreactive and release inflammatory mediators (histamine, tryptase, prostaglandins, and many others) inappropriately. This causes multi-system symptoms: flushing, hives, GI problems, tachycardia, brain fog, and in severe cases, anaphylaxis.

Postural Orthostatic Tachycardia Syndrome (POTS) is a form of dysautonomia characterized by an excessive increase in heart rate (30+ bpm or over 120 bpm) upon standing, accompanied by symptoms like lightheadedness, brain fog, fatigue, and exercise intolerance. The autonomic nervous system, which controls heart rate, blood pressure, digestion, and temperature regulation, doesn’t function properly.

These three conditions sit inside a broader family of related entities that often come up in the same conversation. Hypermobility spectrum disorder (HSD) describes joint hypermobility with pain or instability that does not fully meet the hEDS criteria, dysautonomia is the umbrella term for autonomic nervous system disorders that includes POTS alongside other subtypes, and mastocytosis is a distinct, rarer disease involving an actual excess of mast cells rather than mast cells that are simply overactive, which is the hallmark of MCAS. Clinicians who treat the triad, including allergists and immunologists, dysautonomia specialists, and geneticists who evaluate connective tissue disorders, usually screen for all of these related entities rather than stopping at the first diagnosis.

The Connective Tissue Hypothesis: Why These Three?

The most compelling explanation for the triad connects all three conditions through a common thread: connective tissue.

Here’s the chain of logic:

Step 1: EDS produces defective connective tissue. In hEDS, collagen and related proteins are structurally abnormal. This affects every tissue in the body that relies on collagen for structure – which is essentially everything.

Step 2: Mast cells live in connective tissue. Mast cells are embedded throughout the body’s connective tissue matrix – in skin, gut lining, around blood vessels, and in the respiratory tract. When the connective tissue they’re anchored in is structurally abnormal, mast cells may become mechanically destabilized. Stretching, compression, or other physical forces that would be harmless in normal tissue may trigger mast cell degranulation in defective tissue. This leads to MCAS.

Step 3: Mast cell mediators affect blood vessels, leading to POTS. When mast cells degranulate, they release histamine and other vasoactive mediators that cause blood vessel dilation. In a person with EDS, blood vessels are already more distensible (stretchier) than normal due to collagen defects. Add mast cell-driven vasodilation on top, and blood pools excessively in the lower body upon standing. The heart compensates by racing – and you have POTS.

There’s also a neurological component: defective connective tissue around peripheral nerves may contribute to small fiber neuropathy, which damages the autonomic nerve fibers that control blood vessel tone. This creates yet another pathway to POTS. Our guide to small fiber neuropathy covers how that nerve damage is identified and distinguished from the vascular mechanism above.

What the Research Says About the Shared Mechanism

The connective tissue hypothesis is not just a patient theory. Kohn and Chang (2020), writing in Clinical Reviews in Allergy and Immunology, reviewed the relationship among hEDS, POTS, and MCAS and concluded that the three conditions likely share an underlying connective tissue and mast cell mediated pathway rather than occurring together by chance. Afrin and colleagues (2020) separately published consensus diagnostic criteria for MCAS that are now widely used to confirm the diagnosis in patients who also carry an EDS or POTS diagnosis.

Cardiology and autonomic research groups have documented elevated mast cell mediators, particularly tryptase and histamine metabolites, in a subset of POTS patients during symptomatic episodes, which supports the idea that mast cell degranulation contributes directly to the tachycardia and blood pooling seen in POTS. On the EDS side, small fiber neuropathy has been documented in a meaningful share of hEDS patients, giving the autonomic nervous system a second route to dysfunction beyond mast cell mediated vasodilation.

Prevalence: How Common Is the Overlap?

The exact prevalence of all three conditions co-occurring is difficult to pin down because each one is individually underdiagnosed. However, the available data is striking:

• Studies suggest that 50-66% of hEDS patients meet criteria for MCAS
• An estimated 50-70% of hEDS patients also have some form of dysautonomia, with POTS being the most common type
• Among POTS patients, elevated mast cell mediators have been found in a significant subset, suggesting concurrent MCAS
• A 2019 survey of over 700 hEDS patients found that more than 30% reported a formal diagnosis of all three conditions, with many more reporting symptoms consistent with undiagnosed MCAS or POTS

These numbers likely underestimate the true overlap because many patients with one diagnosed condition haven’t been evaluated for the other two.

Overlapping Symptoms: Untangling the Web

One of the biggest diagnostic challenges is that these conditions produce overlapping symptoms. The following table helps clarify which condition is most likely driving specific symptoms – though in practice, multiple conditions often contribute simultaneously:

The Diagnostic Journey: Why It Takes So Long

The average time from symptom onset to diagnosis across all three conditions is estimated at 7-10 or more years. This isn’t because these conditions are rare – hEDS alone may affect 1 in 500 to 1 in 5,000 people. The delay stems from several factors:

• Symptom fragmentation: Patients see a cardiologist for tachycardia, an allergist for hives, a rheumatologist for joint pain, and a gastroenterologist for GI issues. Each specialist sees their piece but nobody connects the dots.
• Lack of awareness: Many physicians – even specialists – have limited training in MCAS, hEDS, or the triad pattern. MCAS in particular was only formally recognized within the last 15 years.
• Psychological misattribution: The multi-system, fluctuating nature of symptoms frequently leads to diagnoses like “anxiety disorder,” “somatic symptom disorder,” or the particularly unhelpful “it’s all in your head.”
• Normal routine labs: Standard blood work, imaging, and vitals are often normal in these conditions. The tests that detect them (tilt table test, mast cell mediators, Beighton score) are frequently not ordered.

Treatment Strategy: Which Condition to Address First

When all three conditions are present, the question of treatment sequencing matters. Most triad-experienced providers recommend starting with MCAS treatment, and here’s why:

Controlling mast cell activation can improve both POTS and EDS symptoms. If mast cell mediators are driving vasodilation (worsening POTS) and inflammation (worsening joint pain), then stabilizing mast cells can produce improvement across the board. Many patients report that starting H1 and H2 antihistamines, along with a mast cell stabilizer like cromolyn sodium, reduces their POTS symptoms and their pain levels significantly – sometimes more than the treatments targeted specifically at those conditions.

A reasonable treatment sequence:

1. MCAS first: H1 antihistamine (cetirizine or fexofenadine), H2 antihistamine (famotidine), mast cell stabilizer (cromolyn sodium or ketotifen), low-histamine diet
2. POTS alongside: Hydration (2-3L/day), salt loading (3-5g/day), compression garments, graded exercise (reclined exercises initially), and medications if needed (fludrocortisone, midodrine, ivabradine, or beta-blockers)
3. EDS ongoing: Physical therapy focused on joint stabilization (not flexibility!), pain management, bracing as needed, and activity modification

Because POTS is one presentation within the broader dysautonomia treatment landscape, many of the fluid and lifestyle measures above overlap with general autonomic care. Patients who need extra help with the volume and salt loading step sometimes move from oral fluids to structured IV hydration, and our IV hydration clinic directory lists Verified providers who offer it by metro area, with listing order based on relevance rather than any paid ranking.

Regenerative and Supportive Therapies Some Patients Explore

Alongside the core medical treatment sequence above, some triad patients explore therapies aimed at retraining the autonomic nervous system or supporting overall energy and connective tissue function. Evidence for these approaches in MCAS, POTS, and EDS specifically is thinner than the evidence behind antihistamines, fluid loading, and joint focused physical therapy, so they are best treated as adjuncts rather than substitutes for that core plan, and most are cash pay.

Biofeedback and neurofeedback for autonomic regulation. Heart rate variability biofeedback trains patients to influence their own autonomic nervous system responses through breathing and relaxation techniques, which some dysautonomia specialists use alongside standard POTS management. Neurofeedback works on a similar principle for the central nervous system. Our biofeedback therapy directory and neurofeedback therapy guide describe how clinics structure these sessions.

IV nutrient support. Patients dealing with the fatigue and GI malabsorption common to all three conditions sometimes add NAD IV therapy or general IV therapy to their regimen. These remain cash pay services with limited condition specific research, and a well run clinic will say so plainly rather than suggesting they replace mast cell stabilization or autonomic medication.

Whatever combination of therapies you consider, keep in mind that listing order on a clinic directory is not a paid ranking, that Featured slots are labeled and capped, and that a Verified badge means a clinic completed credential checks rather than a payment. Regenerated.com itself is free for patients to use, and being listed in the directory is not an endorsement of any single provider or protocol. Our guide to how Featured, Verified, and organic listings differ explains the distinction in more detail.

Finding a Provider Who Understands the Triad

This is, frankly, one of the hardest parts. The specialists most likely to understand the interconnections include:

• Immunologists familiar with MCAS – not all immunologists recognize MCAS, but those who do are often aware of the triad
• Dysautonomia specialists – neurologists or cardiologists who subspecialize in autonomic dysfunction, particularly at academic centers with POTS clinics
• Geneticists – particularly those who evaluate connective tissue disorders; a genetics evaluation is the formal path to an hEDS diagnosis
• Integrative or functional medicine practitioners – some have developed expertise in the triad, though quality varies widely

Patient advocacy organizations such as The Ehlers-Danlos Society, Dysautonomia International, and The Mast Cell Disease Society maintain provider directories that can help you find knowledgeable clinicians in your area.

Frequently Asked Questions

Can you have two of the three conditions without the third?

Absolutely. While the triad is common, many patients have EDS without MCAS, POTS without EDS, or MCAS without POTS. The triad represents the full spectrum of the connective tissue-immune-autonomic dysfunction pattern, but partial presentations are equally valid. If you have any one of the three, it’s worth screening for the others – but you shouldn’t assume you’ll inevitably develop all three.

Is the triad genetic?

EDS is genetic (though the gene for hEDS hasn’t been identified yet). MCAS and POTS aren’t considered purely genetic disorders, but there appears to be a hereditary predisposition – many patients report family members with similar symptoms, even if undiagnosed. The triad tends to cluster in families, suggesting a shared genetic susceptibility to connective tissue dysfunction that creates the conditions for all three to develop.

My doctor says MCAS isn’t a real diagnosis. What should I do?

This remains frustratingly common, particularly among allergists trained in traditional mast cell disease (mastocytosis). MCAS is recognized in the medical literature and has established diagnostic criteria (both the Valent/consensus criteria and the broader Afrin criteria). If your doctor doesn’t recognize MCAS, seek a second opinion from an immunologist or allergist who specifically lists mast cell disorders in their expertise. The diagnosis is real; the knowledge gap among providers is the problem.

Can the triad be managed well enough to live a normal life?

Many patients achieve significant improvement with appropriate treatment and reach a quality of life that, while not symptom-free, is functional and meaningful. The key is in-depth management: treating all three conditions simultaneously, identifying and avoiding personal triggers, building a knowledgeable medical team, and pacing activities. Complete remission is uncommon, but substantial improvement is the norm with proper care.

What is hypermobility spectrum disorder, and is it different from hEDS?

Hypermobility spectrum disorder (HSD) describes joint hypermobility with pain or instability that does not meet the full diagnostic criteria for hypermobile EDS. Patients with HSD can still develop MCAS and POTS alongside it, since the connective tissue, mast cell, and blood vessel mechanism described above does not require a formal hEDS diagnosis. If your hypermobility testing falls short of the hEDS threshold, it is still worth screening for MCAS and POTS rather than assuming the triad pattern does not apply to you.

Can children have the MCAS-POTS-EDS triad?

Yes. Joint hypermobility often appears first in childhood or adolescence, and POTS frequently emerges or worsens during the growth spurts of puberty. MCAS symptoms such as flushing, hives, and GI complaints can appear at any age. Pediatric dysautonomia specialists and pediatric allergists or immunologists familiar with MCAS are useful starting points, and a genetics evaluation can clarify an EDS diagnosis once hypermobility and other features are documented.

Related Reading

This article is part of our full MCAS resource library. For a complete overview of mast cell activation syndrome, see our full pillar guide: MCAS: The Complete Guide. You may also find these related guides helpful: POTS Treatment and Ehlers-Danlos Syndrome Diagnosis.

For a closer look at how any two of these conditions interact on their own, see how MCAS and POTS interact and the EDS and POTS connection.